We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.39B
AUM Growth
-$132M
Cap. Flow
-$296M
Cap. Flow %
-5.49%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$168M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$151M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$108M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$65.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HELP
101
Cybin Inc
HELP
$961M
$5.08M 0.09%
275,095
-1,860
-0.7% -$50.4K
LLY icon
102
CALL
Eli Lilly
LLY
$1.02T
$4.85M 0.09%
+15,000
New +$4.75M
HRTX icon
103
Heron Therapeutics
HRTX
$58.8M
$4.74M 0.09%
+1,123,000
New +$4.39M
SRRK icon
104
Scholar Rock
SRRK
$5.77B
$4.63M 0.09%
667,943
-408,597
-38% -$3.4M
APLT
105
DELISTED
Applied Therapeutics
APLT
$3.95M 0.07%
4,250,000
– –
CALC icon
106
CalciMedica
CALC
$13.2M
$3.92M 0.07%
59,476
– –
VIGL
107
DELISTED
Vigil Neuroscience
VIGL
$3.74M 0.07%
411,191
– –
SGEN
108
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
$3.42M 0.06%
25,000
-25,000
-50% -$4.07M
ACHL
109
DELISTED
Achilles Therapeutics
ACHL
$3.31M 0.06%
1,463,251
-121,594
-8% -$344K
AMRX icon
110
Amneal Pharmaceuticals
AMRX
$5.9B
$3.2M 0.06%
+1,583,490
New +$4.44M
DNTH icon
111
Dianthus Therapeutics
DNTH
$5.88B
$3.17M 0.06%
140,685
– –
BNR
112
Burning Rock Biotech
BNR
$124M
$3.07M 0.06%
128,282
-10,698
-8% -$345K
HARP
113
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.94M 0.05%
302,591
-1,360
-0.4% -$25.4K
DYN icon
114
Dyne Therapeutics
DYN
$3.38B
$2.8M 0.05%
+220,400
New +$2.53M
LENZ
115
LENZ Therapeutics
LENZ
$134M
$2.69M 0.05%
121,202
– –
TARA icon
116
Protara Therapeutics
TARA
$226M
$2.46M 0.05%
830,641
– –
AFIB
117
DELISTED
Acutus Medical Inc
AFIB
$2.33M 0.04%
2,648,386
– –
LOGC
118
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2.31M 0.04%
8,466,783
– –
PYXS icon
119
Pyxis Oncology
PYXS
$274M
$1.67M 0.03%
+848,252
New +$2.22M
IMDX
120
Insight Molecular Diagnostics
IMDX
$128M
$1.37M 0.03%
94,138
-47,752
-34% -$827K
OMIC
121
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$1.35M 0.03%
18,023
– –
EPIX
122
DELISTED
ESSA Pharma
EPIX
$1.17M 0.02%
+640,645
New +$1.69M
BOLT icon
123
Bolt Biotherapeutics
BOLT
$7.67M
$1.14M 0.02%
+38,553
New +$1.6M
GLUE icon
124
Monte Rosa Therapeutics
GLUE
$1.12B
$960K 0.02%
+117,455
New +$1.08M
HLSQ
125
Tessera Defense and Homeland Security Inc.
HLSQ
$2.86M
$957K 0.02%
1,481
– –
3 4
5
6 7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39B, down 2.4% from $5.52B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed withdrew a net $296M in Q3 2022, closing 25 positions and reducing 31 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $168M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Third Harmonic Bio worth $110M.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168M.
  • OrbiMed's ten largest holdings make up 31% of its $5.39B portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39B.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.